More and more evidence confirms the theory that the intake of cereal products containing gluten may play an important role in the pathogenesis of many diseases. There are also premises indicating the relationship between the so-called gluten-related diseases and the development and course of mental disorders, including schizophrenia.The aim of this article is to review the literature on the potential relationship between the consumption of gluten and schizophrenia, considering the etiopathogenesis and the role of gluten-free diet in the treatment of schizophrenia.Methods: There were analysed available research papers in PubMed and Google Scholar with the key words: schizophrenia, gluten-related disorders, allergy to grain products, celiac disease, microbiota, immune system, exorphins and time span: 1960-2016 .Conclusions: Existing research results indicate a possible relationship between diet rich in grain products with high gluten content and the occurrence or exacerbation of schizophrenia symptoms. However, further studies are necessary to: 1) identify groups of patients for whom the consumption of cereal products (gluten) is associated with a particular risk of schizophrenia exacerbation, 2) determine the mechanisms relating the consumption of gluten with the mental state of schizophrenic patients, 3) get the possible benefits of implementing gluten-free diet in patients with schizophrenia.Keywords: schizophrenia, gluten, celiac disease, gluten-related disorders, allergy to gluten. StreszczeniePrzybywa dowodów na to, iż w patogenezie wielu chorób istotną rolę może odgrywać spożywanie produktów zbożowych zawierających gluten. Istnieją także przesłanki wskazujące na związek tzw. chorób glutenozależnych z powstawaniem i przebiegiem zaburzeń psychicznych, w tym schizofrenii.Celem niniejszego artykułu jest przegląd literatury na temat potencjalnego związku pomiędzy spożyciem glutenu a schizofrenią, z uwzględnieniem etiopatogenezy oraz roli diety bezglutenowej w terapii schizofrenii.Metoda: Analizie poddano dostępne artykuły z bazy PubMed oraz Google Scholar przy użyciu słów-kluczy: schizofrenia, nadwrażliwość na gluten, alergia na produkty zbożowe, celiakia, mikrobiota, układ immunologiczny, egzorfiny oraz deskryptorów czasowych: 1960-2016 rok.Wnioski: Dotychczasowe wyniki badań wskazują na możliwy związek diety bogatej w produkty zbożowe z dużą zawartością glutenu na występowanie lub zaostrzanie objawów schizofrenii. Konieczne są jednak dalsze badania celem: 1) identyfikacji grup pacjentów, dla których spożywanie produktów zbożowych (glutenu) wiąże się ze szczególnym ryzykiem pogorszenia przebiegu schizofrenii, 2) ustalenia mechanizmów łączących spożywanie glutenu ze stanem psychicznym pacjentów ze schizofrenią, 3) możliwych korzyści z wdrożenia diety bezglutenowej u pacjentów ze schizofrenią.
AbstractΩ-3 unsaturated fatty acids are compounds belonging to the group of essential fatty acids (EFAs). The history of the discovery of EFAs dates back to the 1930s of the twentieth century, however, growing interest in ω-3 EFAs in the context of mental health has been observed since the year 2000. In view of their multidirectional action, these compounds are a promising form of adjunctive therapy of many illnesses, including psychiatric disorders. The present article aims to review the literature on the clinical applicability of ω-3 EFAs in treating schizophrenia. We present the results of preclinical studies in this area and the mechanisms of ω-3 EFAs action discussed by the authors. The randomized controlled trials (RCTs) evaluating the possibility of using ω-3 EFAs in schizophrenia are characterized in detail. The results of the tests are not clear, which may result from the methodological diversity of interventions made. Ω-3 EFAs seem to be a promising form of adjunctive therapy of schizophrenia. Further research is needed, which will allow for defining groups of patients in which intervention will bring the expected results.
Introduction: Trichotillomania is a mental disorder characterized by a repetitive and compulsive hair pulling, classified in ICD-10 to a group of habit and impulse disorders, and in the DSM-5 to the group of obsessive-compulsive disorders.Aim: The aim of the study is to present on the basis of case study:1). the importance of traumatic family experiences in releasing as well as maintaining the symptoms of Trichotillomania, 2). comprehensive medical care, the application of which has resulted in a beneficial therapeutic effect.Results: In the described case of 16-year-old patient, Trichotillomania was triggered by traumatic events related to lack of support and family stabilization resulting from parental disputes and grandfather’s death, when she was 11 years old. The subsequent years of her life, in spite of the divorce of her parents and their separate residence, abounded in periods of turbulent quarrels between the parents in which she was involved. Each time this type of incident was associated with the recurrence of behavior associated with Trichotil-lomania, the course of which was more severe with the occurrence of self-harm and suicidal thoughts.Conclusions: 1. In the described case, traumatic events and pathological relations of the immediate family members were not only thetriggering factor, but also maintaining the Trichotillomania symptoms. 2. In accordance with the guidelines of Trichotillomania Learning Center-Scientific Advisory Board (2008), the use of a comprehensive treatment including both the patient - individual psycho-therapy (especially cognitive-behavioral therapy) and pharmacotherapy, as well as her family (family psychotherapy, family mediation, workshops for parents), brought about positive therapeutic effects.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.